-
- Celltrion stated Sampinute yields coronavirus test results within 10 minutes.
- Shares of Celltrion Inc mounted by 4.6 percent.
- Shares of Celltrion Pharm and Celltrion Healthcare surged 4.6 percent and 1.6 percent, respectively.
THDNewsDesk, SEOUL: On October 26, South Korea’s Celltrion Inc stated that it had taken emergency use authorization (EUA) from the US Food & Drug Administration (FDA) expeditious Covid-19 testing kit, Sampinute, increased the shares of the Company and its associates.
Celltrion stated Sampinute yields coronavirus test results within 10 minutes. The results are with a sensitivity of approximately 94 percent.
As per the Company’s statement, the authorization came in late July after three months of soliciting permission. The product was available in August in the United States.
In a statement, “(The company) is planning to supply Sampinute across the United States through local wholesalers as it believes the demand for rapid diagnosis kits will be high, mainly among large businesses and government agencies that are about to return to work after telecommuting.”
Shares of Celltrion Inc mounted by 4.6 percent, while Celltrion Pharm and Celltrion Healthcare surged 4.6 percent and 1.6 percent, respectively. Though, Broader Kospi was trading below 0.1 percent as of 0208 GMT.
Celltrion’s Covid test received the US Emergency use authorisation (EUA)
South Korea's Celltrion Inc stated that it had taken Emergency use authorisation (EUA) from the US Food & Drug Administration (FDA) for its expeditious Covid-19 testing kit
